266
Secretogranin II (SgII)
biomarker and disease
CNS diseases, 28
SN serum levels, heart failure, 28
tumors, 27–28
gene organisation and regulation, 27
hormone secretion and tumorigenesis, 44
prostate cancer, 44
proteolytic processing of, 23
secretoneurin
angiogenesis and vasculogenesis,
30–31
cardiomyocytes, 32
cerebral ischemia, 32
high vascular risk, animal models of,
32–33
immune system, 30
nervous system, 29–30
phylogenetic conservation of, 25–26
wound healing, 31
secretory granule biogenesis, 29, 40
secretory proteins, sorting and release
of, 29
structure and posttranslational
modifications, 22–23
subcellular localisation, LDVs, 24
tissue expression and secretion from cell,
24–25
Secretoneurin (SN) peptide
phylogenetic conservation of, 25–26
physiological functions of
angiogenesis and vasculogenesis,
30–31
cardiomyocytes, 32
cerebral ischemia, 32
high vascular risk, animal models of,
32–33
immune system, 30
nervous system, 29–30
wound healing, 31
Serine protease inhibitor, 214
Serpinin (Serp), 9, 224
AtT20 cells
expression and characterization,
214–217
pGlu-serpinin, expression and secretion
of, 217–218
cardiac effects of, 156
AKT/eNOS/cGMP/PKG pathway, 155
β-adrenergic-like cardiac modulators,
155
β1-AR/AC/cAMP/PKA pathway,
126, 155
ERK1/2 and GSK3β
phosphorylation, 127
Serp-Ala29Gly and pGlu-Serp,
125–127
cardioprotection, 184–185
cell death, 222–223
discovery of, 214
in granule biogenesis, 220–222
organs and nervous system
adrenal medulla and heart, 218
CNS, pGlu-serpinin, 219–220
eye, expression and localization of, 220
physiological functions, 85
serpinin-RRG, anti-angiogenesis effect of,
224, 226
Serum-response element (SRE), 27
SgII. See Secretogranin II (SgII)
Signal transducer and activator of transcription
3 (STAT3), 178, 180
Single nucleotide polymorphisms (SNPs),
human CHGA gene
autonomic activity and blood pressure
CHGA promoter SNPs, 201–202
CHGA 3'-UTR, 202–203
catecholamines, 196
functional genetic polymorphisms
CST domain, 206–208
PST domain, 204–205
functional genetic variations, 197, 201
gene regulatory regions, discovery of,
197–199
haplotype distribution, 200
hypertensive nephrosclerosis, 203–204
resequencing strategy and identified
variants in, 198
systematic polymorphism, 197
Small bowel Crohn’s disease, 44
Soluble tumor necrosis factor receptors
(sTNF-Rs), 89
Spontaneously hypertensive rats (SHR) heart,
106–109
Stathmins, 42, 43
Survivor Activating Factor Enhancement
(SAFE) pathway, 177, 179, 180
Sympatho-adrenal neuroendocrine (SAN)
activity, 99, 101–102
Systemic inflammatory response syndrome
(SIRS), 59–61T
Thrombin, 88
Transcriptome/proteome-wide approach, 43
Trans-Golgi network (TGN) membrane,
39–40, 42–43, 45
Tumor necrosis factor α (TNFα),
86, 91, 161, 180Index